Abstract

This invention discloses new targeted conjugates for the delivery of a compound, and particularly, a steroid, to vascular endothelial cells. The conjugates comprise two components, preferably linked by a selectively-hydrolyzable bond, such as an acid-labile bond or enzyme-sensitive bond. The first component, a polyanionic polymer, and preferably, a polysulphated polymer such as a heparin-derivative, specifically directs the conjugate to vascular endothelial cells. The second component is a selected agent, such as asteroid, which exerts a specific effect on the target cell following its release. In particular, the present invention provides novel conjugated angiogenesis inhibitors, for use in the treatment of pathogenic conditions including cancer, arthritis, and diabetic blindness. An inhibitor comprising a heparin derivative and the anti-angiogenic steroid, cortisol, is herein shown to be markedly acid-labile, to suppress DNA synthesis and cell migration in human umbilical vein endothelial cells, to retard or abolish (depending on the route of injection) the vascularization of sponges in vivo and to retard lung tumor growth in mice by 65%. No adverse effects of the conjugate were detected, and equivalent treatments with a mixture of heparin plus cortisol were significantly less effective in all cases.

Other References

• van Rijn et al., "Selective Binding of Heparina to Human Endothelial Cells. Implications for Pharmacokinetics" Thrombosis Research, 45(3):211-222, 1987
• Barzu et al., "Endothelial Binding Sites for Heparin," Biochemical Journal, 238:847-854, 1986
• Barzu et al., "Binding and Endocytosis of Heparin by Human Endothelial Cells in Culture," Biochimica et Biophysica Acta, 845:196-203, 1985
• Mahadoo et al., "Vascular Sequestration of Heparin," Thrombosis Research, 12(1):79-90, 1977
• Hiebert & Jaques, "The Observation of Heparin on Endothelium After Injection," Thrombosis Research, 8(2):195-204, 1976
• Danishefsky, "Synthesis and Properties of Heparin Derivatives," In `Heparin: Structure, Function and Clinical Implications`, Proceedings of the International Symposium, St. Louis, May 1974, R. A. Bradshaw & S. Wesster, Eds., Plenum Press, New York & London, 1975, pp. 105-118
• Danishefsky & Siskovic, "Conversion of Carboxyl Groups of Mucopolysacchaides into Amides of Amino Acid Esters," Carbohydrate Research, 16:199-205, 1971
• Trouet et al., "A Covalent Linkage Between Daunorubicin and Proteins that is Stable in Serum and Reversible by Lysosomal Hydrolases, as Required for a Lysosomotopic Drug-Carrier Conjugate: In Vitro and In Vivo Studies," Proceedings of the National Acadamy of Sciences U.S.A., 79:626-269, 1982
• Benrezzak et al., "Evaluation of Cortisone-Heparin and Cortisone-Maltose Tetrapalmitate Therapies Against Rodent Tumors. I. Biological Studies," Anticancer Research, 9:1883-1888, 1989
• Folkman et al., "Control of Angiogenesis with Synthetic Heparin Substitutes," Science, 243:1490-1493, 1990
• Sakamoto & Tanaka, "Mechanism of the Synergistic Effect of Heparin and Cortisone Against Angiogenesis and Tumor Growth," The Cancer Journal, 2(1):9-13, 1988
• Sakamoto et al., "Inhibitory Effects of Heparin Plus Cortisone Acetate on Endothelial Cell Growth Both in Cultures and in Masses," Journal of the National Cancer Institute, 78(3):581-585, 1987
• Ingber et al., "A Possible Mechanism for Inhibition of Angiogenesis by Angiostatic Steroids: Induction of Capillary Basement Membrane Dissolution," Endocrinology, 119(4):1768-1775, 1986
• Crum et al., "A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment," Science, 230:1375-1378, 1985
• Folkman et al., "Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone," Science 221:719-725, 1983
• Pino, "Binding and Endocytosis of Heparin-Gold Conjugates by the Fenestrated Endothelium of the Rat Choriocapillaris," Cell Tissue Research, 250:257-266, 1987
• Bjornsson et al., "Effects of N-Deacetylation and N-Desulfation of Heparin on its Anticoagulant Activity and in Vivo Disposition," Jrnl. Pharmacol. and Exp. Therapeut., 245:804-808, 1988
• International Search Report, mailed Jul. 22, 1993
• Fenselau & Adams, "Heparin Conjugates: Novel Antiangiogenic Agents For Possible Use In Retinopathy Treatment," Invest. Ophtamol. Visual. Sci 29:403, Abstract No. 7, 1988
• Jacobs & Wan Kim, "In Vitro Bioactivity of a Synthesized Prostaglandin E₁ -Heparin Conjugate," Journal of Pharmaceutical Science, 75(2): 172-175, 1986
• LeBaron et al., "Binding of Heparan Sulfate to Type V Collagen: A Mechanism of Cell Substrate Adhesion," The Journal of Biological Chemistry, 264(14): 7950-7956, 1989
• Pasternak et al., "Macromolecular Naloxone: A Novel Long-Acting PolymerBound Drug," Life Science, 18(9), 976-981, May 1, 1976
• Spare et al., "Controlled Release from Glycosaminoglycan Drug Complexes," In Controlled Release Delivery Systems, Marcel Dekker, Inc. New York, 1983, pp. 107-11